THE GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE TO REACH USD 4 BILLION BY 2026, GROWING AT A CAGR OF 13% DURING THE FORECAST PERIOD

Vaccine Contract Manufacturing Market Size, Share, Trends Analysis Report by Scale of Operation (Commercial, Clinical, and Preclinical); Vaccine Type (Sub-unit, Live Attenuated, Inactivated, RNA, and Others); Services (Fill/Finish, Analytical & QC Studies, Cell/Virus Banking, and Others); and Geography (North America, Europe, APAC, Latin America, and Middle East & Africa); Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021–2026

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

377 Pages

icon-table

161 Tables

icon-chart

203 Charts

icon-region

5 Regions

icon-country

18 Countries

icon-company

62 Companies

icon-market

4 Market Segment

GLOBAL VACCINE CONTRACT MANUFACTURING MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) 4 BILLION (2026)
CAGR 13% (2021–2026)
Base Year 2020
Forecast Year 2021–2026
Market Segments Scales of Operation (Commercial, Clinical, and Preclinical); Vaccine Type (Sub-unit, Live Attenuated, Inactivated, RNA, and Others); Services (Fill/Finish, Analytical & QC Studies, Cell/Virus Banking, and Others)
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Countries Covered US, Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, Australia, India, Brazil, Mexico, Argentina, Saudi Arabia, Turkey, South Africa

VACCINE CONTRACT MANUFACTURING MARKET INSIGHTS

The global vaccine contract manufacturing market size to reach USD 4 billion by 2026, growing at a CAGR of 13% during the period 2021-2026. The global market has experienced radical transformations after the outbreak of the COVID-19 pandemic, which has been a massive health catastrophe. The commercial segment accounted for 64.53% of the global vaccine contract manufacturing market share in 2020. This is mainly due to the requirement of large-scale production of vaccines, especially during epidemics/pandemics.

Companies such as Johnson & Johnson, AstraZeneca-University of Oxford, Pfizer-BioNTech, Moderna, Novavax, Inovio, and Vaxart have formed international alliances to fast-track development and clinical trials and simultaneously set up vaccine manufacturing and distribution networks worldwide. 

IMPACT OF COVID-19

A new era of vaccine and biological drug development has prevailed since the advent of the COVID-19 virus. The global pandemic has fueled vaccine innovations with the rapid acceleration of RNA-based COVID vaccines. Contract manufacturing companies are working to increase the availability of COVID-19 vaccines across the globe. In the development of the COVID-19 vaccine, pharma companies, CMOs, and suppliers are racing against time to introduce a larger production and supply chain plan so the vaccines can reach people speedily and securely. Vaccine sponsors as large as AstraZeneca and Johnson & Johnson are using CMOs for their pipeline vaccines. AstraZeneca’s AZD-1222, the COVID-19 vaccine candidate, has made manufacturing agreements with 12 service providers, including key players such as Emergent BioSolutions, Novasep, Catalent, and Merck, for its excess capacity manufacturing.

In Europe, the mass production of the COVID-19 vaccine is increasing at a faster rate. For instance, Novavax is utilizing its recently acquired manufacturing facility located in Bohumil in the Czech Republic to produce its own vaccine. Sanofi is investing more than USD 610 million in an advanced production site located in Neuville-sur-Saône as well as in a new vaccine research center in Marcy-l’Etoile. Such strategies will help the mass production of vaccines throughout the world.

GEOGRAPHICAL MARKET SHARE

North America contributed the highest revenue with a market share of 35.40% in the global vaccine contract manufacturing market share in 2020. North America has the most widespread contract manufacturing organizations (CMOs), with nearly 40 CMOs present at several US locations. The US accounted for over 90% of the North American vaccine contract manufacturing market share. The market observes the highest growth in this region due to the presence of major biopharmaceutical companies for clinical studies, increasing populations, the spread of bacterial and viral infections, growing hospitalization, and the growing demand for vaccinations.

Europe accounted for the second-highest share of 26% in the vaccine contract manufacturing market in 2020. The increasing elderly population, prevalence of bacterial and viral infections, increasing demand for new vaccinations, and expanding biopharma and biotech industry are major factors contributing to the growth of contract manufacturing in the Europe region. 

APAC is expected to emerge as the fastest-growing market due to the prevalence of infectious diseases and high adoption of vaccinations to prevent these diseases. APAC is expected to witness the highest absolute growth of 118.91% and the highest CAGR of 13.95% during the forecast period.

SNIPPETS

  • The spread of infectious diseases across regions and the subsequent implementation of vaccination programs have raised the clinical demand for vaccines, thereby driving the market growth.
  • The vaccine contract manufacturing market in India expect to grow at a CAGR of over 15% during 2020–2026.
  • The clinical vaccine contract manufacturing market is likely to observe an absolute growth of over 113% during the forecast period.
  • The sub-unit market is likely to account for the highest incremental growth of over USD 633 million during the forecast period.
  • APAC is likely to observe the highest CAGR because of the high prevalence of infectious diseases, high demand for vaccine programs, and the presence of several contract manufacturers.

GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SEGMENTATION

This research report includes a detailed segmentation by

  • Scale of Operation
  • Vaccine Type
  • Services
  • Geography

The global commercial vaccine contract manufacturing market accounted for over 64% in 2020.

There has been a high demand for contract manufacturing services due to the growth in infectious diseases and the onset of endemics and pandemics worldwide. North America expects to contribute maximum revenue to the commercial vaccine market due to the increased focus to prevent deaths caused by vaccine-preventable diseases. The emergence of the RNA platform has accelerated the vaccine development process.

The clinical vaccine contract manufacturing market is expected to witness an incremental growth of over USD 492 million during the forecast period.

Several serums are in the pipeline for wide-ranging contagious diseases and COVID-19, which are likely to boost the market growth. The preclinical segment accounted for a share of 13% of the global vaccine contract manufacturing market in 2020. Growing populations, healthcare awareness, demand for newer vaccination products, increasing global vaccination coverage are also some of the factors for the increased need for immunizations globally.

Sub-unit vaccines accounted for a major share of approx. 34% in 2020, and they are likely to witness the highest incremental growth of over USD 633 million during the forecast period.

Growing infectious diseases leading to endemic/pandemics, majorly due to decreasing immunization coverage in many regions, have made national and international bodies implement vaccination programs strictly, allowing more people to get vaccinated. This is likely to increase the demand for vaccine production and benefit CMOs’ expertise in the manufacturing services. Contract manufacturing service agreements are high for recombinant vector COVID-19 vaccines.

The global live-attenuated vaccines contract manufacturing market expects to cross over USD 1 billion by 2026.

Live attenuated serums are among the most widely used vaccination technologies. They have complex manufacturing requirements, which increase pharma and biotech R&D budgets. Therefore, companies try to meet vaccine demands via a low-cost and highly effective manufacturing process, thereby facilitating contract manufacturing services.

The fill/finish services market expects to grow at a CAGR of approx. 13% during 2020-2026.

Fill/finish services are subject to extreme scrutiny by regulatory agencies and tend to be costly in the manufacturing process. Hence, vaccine manufacturers outsource these services to CMOs, which help them meet unexpected demands, source policies or better matching scales. Moreover, biopharmaceutical companies outsource fill-and-finish needs to gain access to specialized technology. CMOs are extremely helpful in meeting balanced production volumes and commercial validation of manufactured products. Hence, the growth in biopharmaceuticals is likely to fuel the demand for fill-and-finish contract services.

COMPETITOR MARKET SHARE

Ajinomoto BioPharma, Albany Molecular Research Institute, Catalent, Cytovance Biologics, Emergent Biosolutions, Fujifilm Diosynth Biotechnologies, and GlaxoSmithKline are a few vendors accounting for the global vaccine contract manufacturing market share. Established players are entering into strategic alliances and co-marketing agreements to elevate the market competitiveness and penetration. They also make long-term relationships with distributors and suppliers for scale-up production and expand geographical presence in the market. North America offers a high quantity of contract manufacturing service offerings. Europe and APAC have a few prominent players and several small and mid-sized vendors. Emerging economies, including China, India, Brazil, and Mexico, are likely to offer significant growth opportunities for vendors.

The global vaccine contract manufacturing market research report includes in-depth coverage of the market dynamics with revenue, supply chain, and forecast insights for the following segments:

Scale of Operation

  • Commercial
  • Clinical
  • Pre-clinical

Vaccine Type

  • Sub-unit
  • Live Attenuated
  • Inactivated
  • RNA
  • Others

Services

  • Fill/Finish
  • Analytical & QC Studies
  • Cell/Virus Banking
  • Others

Geography

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • APAC
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Latin America
    • Mexico
    • Brazil
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • Turkey
    • South Africa

Frequently Asked Questions

How big is the vaccine contract manufacturing market?

The global vaccine contract manufacturing market is expected to reach USD 4 billion by 2026, growing at a CAGR of approx.13%.

Which segment is likely to generate the largest revenue during the forecast period?

In terms of services, the fill-and-finish services market expects to generate the highest revenue in the market.

Which region has the largest number of vaccine manufacturers?

North America has the highest number of vaccine contract manufacturers.

Who are the top vaccine manufacturers?

Ajinomoto, Albany Molecular Research (AMRI), Catalent, Cytovance Biologics, Emergent BioSolutions, FUJIFILM, GlaxoSmithKline, IDT Biologika, Lonza, Merck KGaA, Pfizer, Recipharm, Serum Institute of India, and Siegfried Holding are the top vaccine manufacturers.

How has COVID-19 pandemic affected contract manufacturing companies?

The COVID-19 pandemic has boosted the demand for contract manufacturing services with major biopharmaceutical and biotechnological companies outsourcing their vaccine manufacturing processes.

What limitations are associated with the supply of COVID-19 vaccines for CMOs?

Inadequate cold chains, insufficient logistics infrastructure, power shortages, and poor maintenance are the major limitations associated with the supply of COVID-19 vaccines for CMOs.

Download Free Sample

The global vaccine contract manufacturing market by revenue is expected to grow at a CAGR of approx. 13% during the period 2020–2026.

The following factors are likely to contribute to the growth of the vaccine contract manufacturing market during the forecast period:

  • Global COVID-19 Vaccination Programs
  • Manufacturers’ focus on Scale-up Vaccine Production
  • Growing Agreements between Vaccine Developers and Contract Manufacturers
  • Vaccine pipeline boosting demand for Contract Manufacturing

Base Year:                  2020

Forecast Year:           2021–2026

The study considers the global vaccine contract manufacturing market’s present scenario and its market dynamics for the period 2020−2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Prominent Vendors

  • Ajinomoto Bio-Pharma
    • Business Overview
    • Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • Albany Molecular Research (AMRI)
  • Catalent
  • Cytovance Biologics
  • Emergent BioSolutions
  • FUJIFILM
  • GlaxoSmithKline
  • IDT Biologika
  • Lonza
  • Merck KGaA
  • Pfizer
  • Recipharm
  • Serum Institute of India
  • Siegfried Holding

Other Prominent Vendors

  • Cobra Biologics
    • Business Overview
    • Product Offerings
  • Baxter BioPharma Solutions
  • Goodwin Biotechnology
  • KBI Biopharma
  • Sanofi
  • BioMARC
  • Bavarian Nordic
  • Charles River Laboratories
  • Boehringer Ingelheim
  • Samsung Biologics
  • Meridian Life Science
  • Wacker Biotech B.V
  • Jubilant HollisterStier
  • AbbVie
  • Novasep
  • Kemwell Biopharma
  • Northway Biotech
  • Midas Pharma
  • Alcami
  • Cambrex
  • Asymchem
  • Pharmaceutics International Inc. (Pii)
  • Sharp
  • Singota Solutions
  • Thermo Fisher Scientific
  • Kaneka Eurogentec
  • Richter-Helm BioLogics
  • Ology Bioservices
  • Corden Pharma
  • Cerbios Pharma
  • BSP Pharmaceuticals
  • JOINN Biologics
  • Eurofins Scientific
  • ProBioGen
  • Esco Aster
  • Genovior Biotech
  • AGC Biologics
  • EirGenix
  • Amaran Biotech
  • Eden Biologics
  • Abzena
  • Aldevron
  • Cell Culture Company
  • Taron Solutions
  • MabPlex
  • Axcellerate Pharma
  • WuXi Biologics
  • Therapure Biopharma

Scale of Operation

  • Commercial
  • Clinical
  • Pre-clinical

Vaccine Type

  • Sub-unit Vaccines
  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • RNA Vaccines
  • Others

Services

  • Fill/Finish
  • Analytical & QC Studies
  • Cell/Virus Banking
  • Others

Geography

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • APAC
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Latin America
    • Mexico
    • Brazil
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • Turkey
    • South Africa

1            Research Methodology

2            Research Objectives

3            Research Process

 

4            Scope & Coverage

4.1        Market Definition

4.1.1     Inclusions

4.1.2     Exclusions

4.2        Base Year

4.3        Scope of The Study

4.4        Market Segments

4.4.1     Market Segmentation By Scale Of Operation:

4.4.2     Market Segmentation By Vaccine Type

4.4.3     Market Segmentation By Service

4.5.1     Market Segmentation By Geography

 

5            Report Assumptions & Caveats

5.1        Key Caveats

5.2        Currency Conversion

5.3        Market Derivation

 

6            Market at a Glance

7            Introduction

7.1        Overview

7.1.1     Advantages Associated with Contract Manufacturing Organization (CMO)

7.1.2     CMOs Gaining More Acceptance in Biopharmaceutical Industry

7.1.3     Characteristics of An Effective CMO

 

8            Market Opportunities & Trends

8.1        Global Vaccination Programs For COVID-19

8.2        Manufacturers’ Focus On Scale-Up Vaccine Production

8.3        Growing Agreements Between Vaccine Developers And Contract Manufacturers

8.4        Vaccine Pipeline Boosting The Demand For Contract Manufacturing

 

9            Market Growth Enablers

9.1        Favorable Patient Demographics & Growing Vaccinations Of Newborns And Children

9.2        Effect Of Epidemics & Pandemics On Vaccine Development

9.3        Cost-Effective And Time-Saving Services Of Contract Manufacturers

 

10         Market Restraints

10.1      High Costs and Stockout Issues Of Vaccines

10.2      Lack Of Storage Infrastructure & Limitations Associated With Supply Chain

10.3      Vaccination Concerns In Low And Middle Income Countries

 

11         Market Landscape

11.1      Market Overview

11.2      Market Size & Forecast

11.2.1   Vaccine Supply Chain And Procurement During COVID-19

11.3      Five Forces Analysis

11.3.1   Threat Of New Entrants

11.3.2   Bargaining Power Of Suppliers

11.3.3   Bargaining Power Of Buyers

11.3.4   Threat Of Substitutes

11.3.5   Competitive Rivalry

 

12         Scale of Operations

12.1      Market Snapshot & Growth Engine

12.2      Market Overview

12.3      Commercial

12.3.1   Market Overview

12.3.2   Market Size & Forecast

12.3.3   Commercial: Geography Segmentation

12.4      Clinical

12.4.1   Market Overview

12.4.2   Market Size & Forecast

12.4.3   Clinical: Geography Segmentation

12.5      Preclinical

12.5.1   Market Overview

12.5.2   Market Size & Forecast

12.5.3   Preclinical: Geography Segmentation

 

13         Vaccine Type

13.1      Market Snapshot & Growth Engine

13.2      Market Overview

13.3      Sub-Unit Vaccines

13.3.1   Market Overview

13.3.2   Market Size & Forecast

13.3.3   Sub-unit Vaccines: Geography Segmentation

13.4      Live-Attenuated Vaccines

13.4.1   Market Overview

13.4.2   Market Size & Forecast

13.4.3   Live-Attenuated Vaccines: Geography Segmentation

13.5      Inactivated Vaccines

13.5.1   Market Overview

13.5.2   Market Size & Forecast

13.5.3   Inactivated Vaccines: Geography Segmentation

13.6      RNA Vaccines

13.6.1   Market Overview

13.6.2   Market Size & Forecast

13.6.3   RNA Vaccines: Geography Segmentation

13.7      Others

13.7.1   Market Overview

13.7.2   Market Size & Forecast

13.7.3   Others: Geography Segmentation

 

14         Service

14.1      Market Snapshot & Growth Engine

14.2      Market Overview

14.3      Fill/Finish

14.3.1   Market Overview

14.3.2   Market Size & Forecast

14.3.3   Fill/Finish: Geography Segmentation

14.4      Analytical & QC Studies

14.4.1   Market Overview

14.4.2   Market Size & Forecast

14.4.3   Analytical & QC Studies: Geography Segmentation

14.5      Cell/Virus Banking

14.5.1   Market Overview

14.5.2   Market Size & Forecast

14.5.3   Cell/Virus Banking: Geography Segmentation

14.6      Others

14.6.1   Market Overview

14.6.2   Market Size & Forecast

14.6.3   Others: Geography Segmentation

 

15         Geography

15.1      Market Snapshot & Growth Engine

15.2      Geographic Overview

 

16         North America

16.1      Market Overview

16.2      Market Size & Forecast

16.3      North America: Scale Of Operations

16.4      North America: Vaccine Type Segmentation

16.5      North America: Service Segmentation

16.6      Key Countries

16.6.1   US: Market Size & Forecast

16.6.2   Canada: Market Size & Forecast

 

17         Europe

17.1      Market Overview

17.2      Market Size & Forecast

17.3      Europe: Scale Of Operations Segmentation

17.4      Europe: Vaccine Type Segmentation

17.5      Europe: Service Segmentation

17.6      Key Countries

17.6.1   Germany: Market Size & Forecast

17.6.2   UK: Market Size & Forecast

17.6.3   France: Market Size & Forecast

17.6.4   Italy: Market Size & Forecast

17.6.5   Spain: Market Size & Forecast

 

18         APAC

18.1      Market Overview

18.2      Market Size & Forecast

18.3      APAC: Scale Of Operations Segmentation

18.4      APAC: Vaccine Type Segmentation

18.5      APAC: Service Segmentation

18.6      Key Countries

18.6.1   China: Market Size & Forecast

18.6.2   India: Market Size & Forecast

18.6.3   Japan: Market Size & Forecast

18.6.4   South Korea: Market Size & Forecast

18.6.5   Australia: Market Size & Forecast

 

19         Latin America

19.1      Market Overview

19.2      Market Size & Forecast

19.3      Latin America: Scale Of Operations Segmentation

19.4      Latin America: Vaccine Type Segmentation

19.5      Latin America: Service Segmentation

19.6      Key Countries

19.6.1   Brazil: Market Size & Forecast

19.6.2   Mexico: Market Size & Forecast

19.6.3   Argentina: Market Size & Forecast

 

20         Middle East & Africa

20.1      Market Overview

20.2      Market Size & Forecast

20.3      Middle East & Africa: Scale Of Operations Segmentation

20.4      Middle East & Africa: Vaccine Type Segmentation

20.5      Middle East & Africa: Service Segmentation

20.6      Key Countries

20.6.1   South Africa: Market Size & Forecast

20.6.2   Saudi Arabia: Market Size & Forecast

20.6.3   Turkey: Market Size & Forecast

 

21         Competitive Landscape

21.1      Competition Overview

21.2      Market Share Analysis

21.2.1   Ajinomoto

21.2.2   Albany Molecular Research

21.2.3   Catalent

21.2.4   Cytovance Biologics

21.2.5   Emergent BioSolutions

21.2.6   FUJIFILM Diosynth Biotechnologies

21.2.7   GSK

21.2.8   IDT Biologika

21.2.9   Lonza

21.2.10 Merck KGaA

21.2.11 Pfizer

21.2.12 Recipharm

21.2.13 Serum Institute of India

21.2.14 Siegfried

 

22         Key Company Profiles

22.1      AJINOMOTO

22.1.1   Business Overview

22.1.2   Ajinomoto in the Vaccine Contract Manufacturing Market

22.1.3   Service Offerings

22.1.4   Key Strategies

22.1.5   Key Strengths

22.1.6   Key Opportunities

22.2      ALBANY Molecular Research

22.2.1   Business Overview

22.2.2   Albany Molecular Research in the Vaccine Contract Manufacturing Market

22.2.3   Service Offerings

22.2.4   Key Strategies

22.2.5   Key Strengths

22.2.6   Key Opportunities

22.3      Catalent

22.3.1   Business Overview

22.3.2   Catalent in the Vaccine Contract Manufacturing Market

22.3.3   Service Offerings

22.3.4   Key Strategies

22.3.5   Key Strengths

22.3.6   Key Opportunities

22.4      Cytovance Biologics

22.4.1   Business Overview

22.4.2   Cytovance Biologics in the Vaccine Contract Manufacturing Market

22.4.3   Service Offerings

22.4.4   Key Strategies

22.4.5   Key Strengths

22.4.6   Key Opportunities

22.5      Emergent Biosolutions

22.5.1   Business Overview

22.5.2   Emergent BioSolutions in the Vaccine Contract Manufacturing Market

22.5.3   Service Offerings

22.5.4   Key Strategies

22.5.5   Key Strengths

22.5.6   Key Opportunities

22.6      Fujifilm

22.6.1   Business Overview

22.6.2   Fujifilm in the Vaccine Contract Manufacturing Market

22.6.3   Service Offerings

22.6.4   Key Strategies

22.6.5   Key Strengths

22.6.6   Key Opportunities

22.7      GSK

22.7.1   Business Overview

22.7.2   GSK in the Vaccine Contract Manufacturing Market

22.7.3   Service Offerings

22.7.4   Key Strategies

22.7.5   Key Strengths

22.7.6   Key Opportunities

22.8      IDT Biologika

22.8.1   Business Overview

22.8.2   IDT Biologika in the Vaccine Contract Manufacturing Market

22.8.3   Service Offerings

22.8.4   Key Strategies

22.8.5   Key Strengths

22.8.6   Key Opportunities

22.9      LONZA

22.9.1   Business Overview

22.9.2   Lonza in the Vaccine Contract Manufacturing Market

22.9.3   Service Offerings

22.9.4   Key Strategies

22.9.5   Key Strengths

22.9.6   Key Opportunities

22.10    MERCK KGAA

22.10.1 Business Overview

22.10.2 Merck in the Vaccine Contract Manufacturing Market

22.10.3 Service Offerings

22.10.4 Key Strategies

22.10.5 Key Strengths

22.10.6 Key Opportunities

22.11    PFIZER

22.11.1 Business Overview

22.11.2 Pfizer in the Vaccine Contract Manufacturing Market

22.11.3 Service Offerings

22.11.4 Key Strategies

22.11.5 Key Strengths

22.11.6 Key Opportunities

22.12    RECIPHARM

22.12.1 Business Overview

22.12.2 Recipharm in the Vaccine Contract Manufacturing Market

22.12.3 Service Offerings

22.12.4 Key Strategies

22.12.5 Key Strengths

22.12.6 Key Opportunities

22.13    SERUM Institute of India

22.13.1 Business Overview

22.13.2 Serum Institute of India in the Vaccine Contract Manufacturing Market

22.13.3 Service Offerings

22.13.4 Key Strategies

22.13.5 Key Strengths

22.13.6 Key Opportunities

22.14    SIEGFRIED

22.14.1 Business Overview

22.14.2 Siegfried in the Vaccine Contract Manufacturing Market

22.14.3 Service Offerings

22.14.4 Key Strategies

22.14.5 Key Strengths

22.14.6 Key Opportunities

 

23         Other Prominent Vendors

23.1      Cobra Biologics

23.1.1   Business Overview

23.1.2   Service Offerings

23.2      Baxter Healthcare

23.2.1   Business Overview

23.2.2   Service Offerings

23.3      Goodwin Biotechnology

23.3.1   Business Overview

23.3.2   Service Offerings

23.4      KBI Biopharma

23.4.1   Business Overview

23.4.2   Service Offerings

23.5      Sanofi

23.5.1   Business Overview

23.5.2   Service Offerings

23.6      Biomarc

23.6.1   Business Overview

23.6.2   Service Offerings

23.7      Bavarian Nordic

23.7.1   Business Overview

23.7.2   Service Offerings

23.8      Charles River Laboratories

23.8.1   Business Overview

23.8.2   Service Offerings

23.9      Boehringer Ingelheim

23.9.1   Business Overview

23.9.2   Service Offerings

23.10    Samsung Biologics

23.10.1 Business Overview

23.10.2 Service Offerings

23.11    Meridian Life Science

23.11.1 Business Overview

23.11.2 Service Offerings

23.12    Wacker Biotech B.V

23.12.1 Business Overview

23.12.2 Service Offerings

23.13    Jubilant Hollisterstier

23.13.1 Business Overview

23.13.2 Service Offerings

23.14    Abbvie

23.14.1 Business Overview

23.14.2 Service Offerings

23.15    Novasep

23.15.1 Business Overview

23.15.2 Service Offerings

23.16    Kemwell Biopharma

23.16.1 Business Overview

23.16.2 Service Offerings

23.17    Northway Biotech

23.17.1 Business Overview

23.17.2 Service Offerings

23.18    Midas Pharma

23.18.1 Business Overview

23.18.2 Service Offerings

23.19    ALCAMI

23.19.1 Business Overview

23.19.2 Service Offerings

23.20    Cambrex

23.20.1 Business Overview

23.20.2 Service Offerings

23.21    Asymchem

23.21.1 Business Overview

23.21.2 Service Offerings

23.22    Pharmaceutics International

23.22.1 Business Overview

23.22.2 Service Offerings

23.23    Sharp

23.23.1 Business Overview

23.23.2 Service Offerings

23.24    Singota Solutions

23.24.1 Business Overview

23.24.2 Service Offerings

23.25    Thermo Fisher Scientific

23.25.1 Business Overview

23.25.2 Service Offerings

23.26    Kaneka Eurogentec

23.26.1 Business Overview

23.26.2 Service Offerings

23.27    Richter-Helm Biologics

23.27.1 Business Overview

23.27.2 Service Offerings

23.28    OLOGY Bioservices

23.28.1 Business Overview

23.28.2 Service Offerings

23.29    Corden Pharma

23.29.1 Business Overview

23.29.2 Service Offerings

23.30    Cerbios Pharma

23.30.1 Business Overview

23.30.2 Service Offerings

23.31    BSP Pharmaceuticals

23.31.1 Business Overview

23.31.2 Service Offerings

23.32    Joinn Biologics

23.32.1 Business Overview

23.32.2 Service Offerings

23.33    Eurofins Scientific

23.33.1 Business Overview

23.33.2 Service Offerings

23.34    Probiogen

23.34.1 Business Overview

23.34.2 Service Offerings

23.35    ESCO Aster

23.35.1 Business Overview

23.35.2 Service Offerings

23.36    Genovior Biotech

23.36.1 Business Overview

23.36.2 Service Offerings

23.37    AGC Biologics

23.37.1 Business Overview

23.37.2 Service Offerings

23.38    EIRGENIX

23.38.1 Business Overview

23.38.2 Service Offerings

23.39    Amaran Biotech

23.39.1 Business Overview

23.39.2 Service Offerings

23.40    EDEN Biologics

23.40.1 Business Overview

23.40.2 Service Offerings

23.41    ABZENA

23.41.1 Business Overview

23.41.2 Service Offerings

23.42    ALDEVRON

23.42.1 Business Overview

23.42.2 Service Offerings

23.43    Cell Culture Company

23.43.1 Business Overview

23.43.2 Service Offerings

23.44    Taron Solutions

23.44.1 Business Overview

23.44.2 Service Offerings

23.45    MABPLEX

23.45.1 Business Overview

23.45.2 Service Offerings

23.46    AXCELLERATE Pharma

23.46.1 Business Overview

23.46.2 Service Offerings

23.47    WUXI Biologics

23.47.1 Business Overview

23.47.2 Service Offerings

23.48    Therapure Biopharma

23.48.1 Business Overview

23.48.2 Service Offerings

 

24         Report Summary

24.1      Key Takeaways

24.2      Strategic Recommendations

 

25         Quantitative Summary

25.1      Market By Scale Of Operation

25.1.1   North America: Scale of Operations Segmentation

25.1.2   Europe: Scale of Operations Segmentation

25.1.3   APAC: Scale of Operations Segmentation

25.1.4   Latin America: Scale of Operations Segmentation

25.1.5   Middle East & Africa: Scale of Operations Segmentation

25.2      Market By Vaccine Type

25.2.1   North America: Vaccine Type Segmentation

25.2.2   Europe: Vaccine Type Segmentation

25.2.3   APAC: Vaccine Type Segmentation

25.2.4   Latin America: Vaccine Type Segmentation

25.2.5   Middle East & Africa: Vaccine Type Segmentation

25.3      Market By Service

25.3.1   North America: Service Segmentation

25.3.2   Europe: Service Segmentation

25.3.3   APAC: Service Segmentation

25.3.4   Latin America: Service Segmentation

25.3.5   Middle East & Africa: Service Segmentation

25.4      Market By Geography

25.4.1   Commercial: Geography Segmentation

25.4.2   Clinical: Geography Segmentation

25.4.3   Preclinical: Geography Segmentation

25.4.4   Sub-Unit Vaccines: Geography Segmentation

25.4.5   Live-attenuated Vaccines: Geography Segmentation

25.4.6   Inactivated Vaccines: Geography Segmentation

25.4.7   RNA Vaccines: Geography Segmentation

25.4.8   Others: Geography Segmentation

25.4.9   Fill/Finish: Geography Segmentation

25.4.10 Analytical & QC Studies: Geography Segmentation

25.4.11 Cell/Virus Banking: Geography Segmentation

25.4.12 Others: Geography Segmentation

 

26         Appendix

26.1      Abbreviations

             

 

             

List of Exhibits 

Exhibit 1             Segmentation of Global Vaccine Contract Manufacturing Market

Exhibit 2             Market Size Calculation Approach 2020

Exhibit 3             Factors Considered Before a Partnership with Contract Manufacturers

Exhibit 4             Opportunities for Contract Manufacturers

Exhibit 5             Impact of Global Vaccination Programs for COVID-19

Exhibit 6             Impact of Manufacturers’ Focus on Scale-Up Vaccine Production

Exhibit 7             Impact of Growing Agreements Between Vaccine Developers and Contract Manufacturers

Exhibit 8             Vaccine Production Outsourcers from Buyer Groups

Exhibit 9             Impact of Vaccine Pipeline Boosting the Demand for Contract Manufacturing

Exhibit 10           Vaccines in the Pipeline for Various Infectious Diseases

Exhibit 11           DCVMN Pipeline: Number of Vaccine Projects in Development (2019)

Exhibit 12           Impact of Favorable Patient Demographics & Growing Vaccinations of Newborns and Children

Exhibit 13           Disease Incidence in the World 2020 (million)

Exhibit 14           Global Vaccination Coverage of 1-year-olds in 2019

Exhibit 15           Eradication of Major Diseases Through Vaccines in US

Exhibit 16           Impact of Effect of Epidemics & Pandemics on Vaccine Development

Exhibit 17           Number of Epidemic Events During 2011-2017

Exhibit 18           Impact of Cost-Effective and Time-Saving Services of Contract Manufacturers

Exhibit 19           Major Advantages of Engaging with CMOs

Exhibit 20           Impact of High Costs and Stockout Issues of Vaccines

Exhibit 21           Reported Stockouts of Vaccines During 2010-2018

Exhibit 22           Impact of Lack of Storage Infrastructure & Limitations Associated with Supply Chain

Exhibit 23           Major Barriers to Effective Vaccine Handling and Storage

Exhibit 24           Impact of Vaccination Concerns in Low- and Middle-Income Countries

Exhibit 25           Ten Most Frequently Reported Vaccination Concerns in LMICs

Exhibit 26           Global Vaccine Contract Manufacturing Market 2020–2026 ($ million)

Exhibit 27           Global Vaccine Contract Manufacturing Market by Scale of Operations

Exhibit 28           Global Vaccine Contract Manufacturing Market by Geography

Exhibit 29           Global Vaccine Contract Manufacturing Market by Vaccine type

Exhibit 30           Global Vaccine Contract Manufacturing Market by Service

Exhibit 31           Five Forces Analysis 2020

Exhibit 32           Incremental Growth by Scale of Operations 2020 & 2026

Exhibit 33           Global Vaccine Contract Manufacturing Market by Scale of Operations

Exhibit 34           Vaccine Pipeline for Various Infectious Diseases 2020

Exhibit 35           COVID-19 Vaccine Candidates in Various Clinical Stages of Development

Exhibit 36           Global Vaccine Contract Manufacturing Market by Scale of Operations: Incremental Growth

Exhibit 37           Global Vaccine Contract Manufacturing Market by Scale of Operations: Absolute Growth

Exhibit 38           Global Vaccine Contract Manufacturing Market by Commercial Segment: Incremental & Absolute Growth

Exhibit 39           Vaccines in the Pipeline for Various Diseases in 2020

Exhibit 40           Vaccines in the Pipeline by Disease Type in 2020

Exhibit 41           Global Vaccine Contract Manufacturing Market by Commercial Segment 2020–2026 ($ million)

Exhibit 42           Incremental Growth by Geography 2020 & 2026

Exhibit 43           Global Vaccine Contract Manufacturing Market by Clinical Segment: Incremental & Absolute Growth

Exhibit 44           Global Vaccine Contract Manufacturing Market by Clinical Segment 2020–2026 ($ million)

Exhibit 45           Incremental Growth by Geography 2020 & 2026

Exhibit 46           Global Vaccine Contract Manufacturing Market by Preclinical Segment: Incremental & Absolute Growth

Exhibit 47           Global Vaccine Contract Manufacturing Market by Preclinical Segment 2020–2026 ($ million)

Exhibit 48           Incremental Growth by Geography 2020 & 2026

Exhibit 49           Incremental Growth by Vaccine Type 2020 & 2026

Exhibit 50           Global Vaccine Contract Manufacturing Market by Vaccine Type

Exhibit 51           Different Types of COVID-19 Vaccines Under Research by 2020

Exhibit 52           Global Vaccine Contract Manufacturing Market by Vaccine Type: Incremental Growth

Exhibit 53           Global Vaccine Contract Manufacturing Market by Vaccine Type: Absolute Growth

Exhibit 54           Global Vaccine Contract Manufacturing Market by Sub-Unit Vaccines: Incremental & Absolute Growth

Exhibit 55           Global Vaccine Contract Manufacturing Market by Sub-Unit Vaccines 2020–2026 ($ million)

Exhibit 56           Incremental Growth by Geography 2020 & 2026

Exhibit 57           Global Vaccine Contract Manufacturing Market by Live-Attenuated Vaccines: Incremental & Absolute Growth

Exhibit 58           Global Vaccine Contract Manufacturing Market by Live-Attenuated Vaccines 2020–2026 ($ million)

Exhibit 59           Incremental Growth by Geography 2020 & 2026

Exhibit 60           Global Vaccine Contract Manufacturing Market by Inactivated Vaccines: Incremental & Absolute Growth

Exhibit 61           Global Vaccine Contract Manufacturing Market by Inactivated Vaccines 2020–2026 ($ million)

Exhibit 62           Incremental Growth by Geography 2020 & 2026

Exhibit 63           Global Vaccine Contract Manufacturing Market by RNA Vaccines: Incremental & Absolute Growth

Exhibit 64           Global Vaccine Contract Manufacturing Market by RNA Vaccines 2020–2026 ($ million)

Exhibit 65           Incremental Growth by Geography 2020 & 2026

Exhibit 66           Global Vaccine Contract Manufacturing Market by Others: Incremental & Absolute Growth

Exhibit 67           Global Vaccine Contract Manufacturing Market by Others 2020–2026 ($ million)

Exhibit 68           Incremental Growth by Geography 2020 & 2026

Exhibit 69           Incremental Growth by Service 2020 & 2026

Exhibit 70           Global Vaccine Contract Manufacturing Market by Service

Exhibit 71           Major Biopharmaceutical Contract Manufacturing Services

Exhibit 72           Global Vaccine Contract Manufacturing Market by Service: Incremental Growth

Exhibit 73           Global Vaccine Contract Manufacturing Market by Service: Absolute Growth

Exhibit 74           Global Vaccine Contract Manufacturing Market by Fill/Finish: Incremental & Absolute Growth

Exhibit 75           Outsourcing Fill-And-Finish Services to CMOs

Exhibit 76           Global Vaccine Contract Manufacturing Market by Fill/Finish Services 2020–2026 ($ million)

Exhibit 77           Incremental Growth by Geography 2020 & 2026

Exhibit 78           Analytical and QC Services Outsourced by Biopharma Manufacturers

Exhibit 79           Global Vaccine Contract Manufacturing Market by Analytical & QC Studies: Incremental & Absolute Growth

Exhibit 80           Global Vaccine Contract Manufacturing Market by Analytical & QC Studies 2020–2026 ($ million)

Exhibit 81           Incremental Growth by Geography 2020 & 2026

Exhibit 82           Protein Expression Systems Offered by Top CMOs

Exhibit 83           Global Vaccine Contract Manufacturing Market by Cell/Virus Banking: Incremental & Absolute Growth

Exhibit 84           Global Vaccine Contract Manufacturing Market by Cell/Virus Banking 2020–2026 ($ million)

Exhibit 85           Incremental Growth by Geography 2020 & 2026

Exhibit 86           Global Vaccine Contract Manufacturing Market by Others: Incremental & Absolute Growth

Exhibit 87           Biopharma Companies Outsourcing Their Regulatory Requirements

Exhibit 88           Global Vaccine Contract Manufacturing Market by Others 2020–2026 ($ million)

Exhibit 89           Incremental Growth by Geography 2020 & 2026

Exhibit 90           Incremental Growth by Geography 2020 & 2026

Exhibit 91           Global Vaccine Contract Manufacturing Market by Geography

Exhibit 92           Global Vaccine Contract Manufacturing Market by Geography: Key Countries ($ million)

Exhibit 93           Global Vaccine Contract Manufacturing Market by Geography: Incremental Growth

Exhibit 94           Global Vaccine Contract Manufacturing Market by Geography: Absolute Growth

Exhibit 95           Market Share of Major Countries in North America

Exhibit 96           Deaths Caused by Vaccine-Preventable Diseases in North America (2013-2017)

Exhibit 97           Vaccine Contract Manufacturing Market in North America: Key Countries 2020

Exhibit 98           Vaccine Contract Manufacturing Market in North America: Incremental & Absolute Growth

Exhibit 99           Vaccine Contract Manufacturing Market in North America 2020–2026 ($ million)

Exhibit 100        Incremental Growth by Scale of Operations 2020 & 2026

Exhibit 101        Incremental Growth by Vaccine Type 2020 & 2026

Exhibit 102        Incremental Growth by Service 2020 & 2026

Exhibit 103        Incremental Growth in North America 2020 & 2026

Exhibit 104        Major Infectious Diseases Causing Deaths in the US

Exhibit 105        Vaccine Contract Manufacturing Market in the US 2020–2026 ($ million)

Exhibit 106        Number of Deaths Caused by Major Infectious Diseases in Canada

Exhibit 107        Vaccination Coverage in Children Aged 1 Year in Canada

Exhibit 108        Vaccine Contract Manufacturing Market in Canada 2020–2026 ($ million)

Exhibit 109        Market Share of Major Countries in Europe

Exhibit 110        Burden of Vaccine-Preventable Diseases in Europe 2009–2013

Exhibit 111        Vaccine Contract Manufacturing Market in Europe: Key Countries 2020

Exhibit 112        Vaccine Contract Manufacturing Market in Europe: Incremental & Absolute Growth

Exhibit 113        Vaccine Contract Manufacturing Market in Europe 2020–2026 ($ million)

Exhibit 114        Incremental Growth by Scale of Operations 2020 & 2026

Exhibit 115        Incremental Growth by Vaccine Type 2020 & 2026

Exhibit 116        Incremental Growth by Service 2020 & 2026

Exhibit 117        Incremental Growth in Europe 2020 & 2026

Exhibit 118        Deaths Caused by Vaccine-Preventable Diseases in Germany

Exhibit 119        Vaccine Contract Manufacturing Market in Germany 2020–2026 ($ million)

Exhibit 120        Vaccine-Preventable Diseases Causing Deaths in the UK

Exhibit 121        Vaccine Contract Manufacturing Market in the UK 2020–2026 ($ million)

Exhibit 122        Major Infectious Diseases Causing Deaths in France

Exhibit 123        Target Population Immunized for Vaccine-Preventable Diseases

Exhibit 124        Vaccine Contract Manufacturing Market in France 2020–2026 ($ million)

Exhibit 125        Deaths due to Vaccine-Preventable Diseases in Italy

Exhibit 126        Vaccine Contract Manufacturing Market in Italy 2020–2026 ($ million)

Exhibit 127        Major Vaccine-Preventable Diseases Causing Deaths in Spain

Exhibit 128        Vaccine Contract Manufacturing Market in Spain 2020–2026 ($ million)

Exhibit 129        Market Share of Major Countries in APAC

Exhibit 130        Vaccine Contract Manufacturing Market in APAC: Key Countries 2020

Exhibit 131        Vaccine Contract Manufacturing Market in APAC: Incremental & Absolute Growth

Exhibit 132        Vaccine Contract Manufacturing Market in APAC 2020–2026 ($ million)

Exhibit 133        Incremental Growth by Scale of Operations 2020 & 2026

Exhibit 134        Incremental Growth by Vaccine Type 2020 & 2026

Exhibit 135        Incremental Growth by Service 2020 & 2026

Exhibit 136        Incremental Growth in APAC 2020 & 2026

Exhibit 137        Major Vaccine-Preventable Diseases Causing Deaths in China

Exhibit 138        Vaccine Contract Manufacturing Market in China 2020–2026 ($ million)

Exhibit 139        Major Infectious Diseases Causing Mortality in India

Exhibit 140        Vaccine Contract Manufacturing Market in India 2020–2026 ($ million)

Exhibit 141        Deaths Caused due to Various Infectious Diseases in Japan

Exhibit 142        Vaccine Contract Manufacturing Market in Japan 2020–2026 ($ million)

Exhibit 143        Deaths due to Vaccine-Preventable Diseases in South Korea

Exhibit 144        Vaccine Contract Manufacturing Market in South Korea 2020–2026 ($ million)

Exhibit 145        Deaths Caused by Infectious Diseases in Australia

Exhibit 146        Vaccine Contract Manufacturing Market in Australia 2020–2026 ($ million)

Exhibit 147        Market share of major countries in Latin America

Exhibit 148        Deaths Caused by Vaccine-Preventable Diseases

Exhibit 149        Vaccine Contract Manufacturing Market in Latin America: Key Countries 2020

Exhibit 150        Vaccine Contract Manufacturing Market in Latin America: Incremental & Absolute Growth

Exhibit 151        Vaccine Contract Manufacturing Market in Latin America 2020–2026 ($ million)

Exhibit 152        Incremental Growth by Scale of Operations 2020 & 2026

Exhibit 153        Incremental Growth by Vaccine Type 2020 & 2026

Exhibit 154        Incremental Growth by Service 2020 & 2026

Exhibit 155        Incremental Growth in Latin America 2020 & 2026

Exhibit 156        Major Deaths Caused due to Vaccine-Preventable Diseases

Exhibit 157        National Immunization Coverage for Brazil (%)

Exhibit 158        Vaccine Contract Manufacturing Market in Brazil 2020–2026 ($ million)

Exhibit 159        Deaths Caused by Vaccine-Preventable Diseases

Exhibit 160        Vaccine Contract Manufacturing Market in Mexico 2020–2026 ($ million)

Exhibit 161        Deaths Caused due to Vaccine-Preventable Diseases

Exhibit 162        Vaccine Contract Manufacturing Market in Argentina 2020–2026 ($ million)

Exhibit 163        Market Share of Major Countries in the Middle East & Africa

Exhibit 164        Vaccine-Preventable Diseases Causing Mortality in the Middle East & Africa

Exhibit 165        Vaccine Contract Manufacturing Market in the Middle East & Africa: Key Countries 2020

Exhibit 166        Vaccine Contract Manufacturing Market in the Middle East & Africa: Incremental & Absolute Growth

Exhibit 167        Vaccine Contract Manufacturing Market in the Middle East & Africa 2020–2026 ($ million)

Exhibit 168        Incremental Growth by Scale of Operations 2020 & 2026

Exhibit 169        Incremental Growth by Vaccine Type 2020 & 2026

Exhibit 170        Incremental Growth by Service 2020 & 2026

Exhibit 171        Incremental Growth in the Middle East & Africa 2020 & 2026

Exhibit 172        Deaths Caused by Vaccine-Preventable Diseases

Exhibit 173        Target Population Immunized for Vaccine-Preventable Diseases

Exhibit 174        Vaccine Contract Manufacturing Market in South Africa 2020–2026 ($ million)

Exhibit 175        Deaths Caused by Vaccine-Preventable Diseases

Exhibit 176        Vaccine Contract Manufacturing Market in Saudi Arabia 2020–2026 ($ million)

Exhibit 177        Deaths due to Vaccine-Preventable Diseases in Turkey

Exhibit 178        Vaccine Contract Manufacturing Market in Turkey 2020–2026 ($ million)

Exhibit 179        Ajinomoto: Revenue 2017-2019 ($ billion)

Exhibit 180        Ajinomoto: Revenue by Segments 2018-2019 ($ billion)

Exhibit 181        Ajinomoto: Revenue Share by Geographical Region 2019 ($ billion)

Exhibit 182        Catalent: Revenue 2018-2020 ($ million)

Exhibit 183        Catalent: Revenue Share by Geographical Region 2020 & 2019 ($ million)

Exhibit 184        Emergent BioSolutions: Revenue 2018-2020 ($ million)

Exhibit 185        Emergent BioSolutions: Revenue by Segments 2019-2020 ($ million)

Exhibit 186        FUJIFILM: Revenue 2017-2019 ($ billion)

Exhibit 187        FUJIFILM: Revenue by Segments 2018-2019 ($ billion)

Exhibit 188        GSK: Revenue 2017-2020 ($ billion)

Exhibit 189        GSK: Revenue by Segments 2018-2019 ($ billion)

Exhibit 190        GSK: R&D Expenditure During 2018-2019 ($ million)

Exhibit 191        GSK: Revenue Share by Geographical Region During 2018-2019 ($ million)

Exhibit 192        Lonza: Revenue 2018-2019 ($ million)

Exhibit 193        Lonza: Revenue by Segments 2018-2019 ($ million)

Exhibit 194        Lonza: Revenue Share by Geographical Region 2019 ($ million)

Exhibit 195        Merck KGaA: Revenue Share During 2017-2020 ($ billion)

Exhibit 196        Pfizer: Revenue Share 2017-2019 ($ million)

Exhibit 197        Pfizer: Revenue by Segments 2018-2019 ($ million)

Exhibit 198        Pfizer: R&D Expenditure 2017-2019 ($ million)

Exhibit 199        Pfizer: Revenue Share by Geographical Region During 2018-2019 ($ million)

Exhibit 200        Recipharm: Revenue share 2017-2019 ($ million)

Exhibit 201        Recipharm: Revenue Share by Segments 2018-2019 ($ million)

Exhibit 202        Recipharm: Revenue Share by Geography 2018-2019 ($ million)

Exhibit 203        Siegfried: Revenue 2018-2020 ($ million)

             

             

List of Tables    

Table 1               Key Caveats

Table 2               Currency Conversion 2013−2020

Table 3               WHO recommendations for priority use of COVID-19 vaccine during limited supply

Table 4               Current Vaccine Pipeline for Infectious Diseases

Table 5               Vaccines for Various Infectious and Cancer Diseases in Clinical Trials

Table 6               New Vaccine Candidates for Tuberculosis in Preclinical Phase in 2020

Table 7               Types of vaccines available for various infectious diseases

Table 8               Vaccine Contract Manufacturing Market in North America by Scale of Operations 2020−2026 ($ million)

Table 9               Vaccine Contract Manufacturing Market in North America by Scale of Operations 2020−2026 (%)

Table 10             Vaccine Contract Manufacturing Market in North America by Vaccine type 2020−2026 ($ million)

Table 11             Vaccine Contract Manufacturing Market in North America by Vaccine Type 2020−2026 (%)

Table 12             Vaccine Contract Manufacturing Market in North America by Service 2020−2026 ($ million)

Table 13             Vaccine Contract Manufacturing Market in North America by Service 2020−2026 (%)

Table 14             Vaccine Contract Manufacturing Market in Europe by Scale of Operations 2020−2026 ($ million)

Table 15             Vaccine Contract Manufacturing Market in Europe by Scale of Operations 2020−2026 (%)

Table 16             Vaccine Contract Manufacturing Market in Europe by Vaccine type 2020−2026 ($ million)

Table 17             Vaccine Contract Manufacturing Market in Europe by Vaccine type 2020−2026 (%)

Table 18             Vaccine Contract Manufacturing Market in Europe by Service 2020−2026 ($ million)

Table 19             Vaccine Contract Manufacturing Market in Europe by Service 2020−2026 (%)

Table 20             Vaccine Contract Manufacturing Market in APAC by Scale of Operations 2020−2026 ($ million)

Table 21             Vaccine Contract Manufacturing Market in APAC by Scale of Operations 2020−2026 (%)

Table 22             Vaccine Contract Manufacturing Market in APAC by Vaccine Type 2020−2026 ($ million)

Table 23             Vaccine Contract Manufacturing Market in APAC by Vaccine Type 2020−2026 (%)

Table 24             Vaccine Contract Manufacturing Market in APAC by Service 2020−2026 ($ million)

Table 25             Vaccine Contract Manufacturing Market in APAC by Service 2020−2026 (%)

Table 26             Vaccine Contract Manufacturing Market in Latin America by Scale of Operations 2020−2026 ($ million)

Table 27             Vaccine Contract Manufacturing Market in Latin America by Scale of Operations 2020−2026 (%)

Table 28             Vaccine Contract Manufacturing Market in Latin America by Vaccine Type 2020−2026 ($ million)

Table 29             Vaccine Contract Manufacturing Market in Latin America by Vaccine Type 2020−2026 (%)

Table 30             Vaccine Contract Manufacturing Market in Latin America by Service 2020−2026 ($ million)

Table 31             Vaccine Contract Manufacturing Market in Latin America by Service 2020−2026 (%)

Table 32             Vaccine Contract Manufacturing Market in the Middle East & Africa by Scale of Operations 2020−2026 ($ million)

Table 33             Vaccine Contract Manufacturing Market in the Middle East & Africa by Scale of Operations 2020−2026 (%)

Table 34             Vaccine Contract Manufacturing Market in the Middle East & Africa by Vaccine Type 2020−2026 ($ million)

Table 35             Vaccine Contract Manufacturing Market in the Middle East & Africa by Vaccine Type 2020−2026 (%)

Table 36             Vaccine Contract Manufacturing Market in the Middle East & Africa by Service 2020−2026 ($ million)

Table 37             Vaccine Contract Manufacturing Market in the Middle East & Africa by Service 2020−2026 (%)

Table 38             Ajinomoto: Major Service Offerings

Table 39             Albany Molecular Research: Major Service Offerings

Table 40             Catalent: Major Service Offerings

Table 41             Cytovance Biologics: Major Service Offerings

Table 42             Emergent BioSolutions: Major Service Offerings

Table 43             FUJIFILM: Major Service Offerings

Table 44             GSK: Major Service Offerings

Table 45             IDT Biologika: Major Service Offerings

Table 46             Lonza: Major Service Offerings

Table 47             Merck: Major Service Offerings

Table 48             Pfizer: Major Service Offerings

Table 49             Recipharm: Major Service Offerings

Table 50             Serum Institute of India: Major Service Offerings

Table 51             Siegfried: Major Service Offerings

Table 52             Cobra Biologics: Major Service Offerings

Table 53             Baxter Healthcare: Major Service Offerings

Table 54             Goodwin Biotechnology: Major Service Offerings

Table 55             KBI Biopharma: Major Service Offerings

Table 56             Sanofi: Major Service Offerings

Table 57             BioMARC: Major Service Offerings

Table 58             Bavarian Nordic: Major Service Offerings

Table 59             Charles River Laboratories: Major Service Offerings

Table 60             Boehringer Ingelheim: Major Service Offerings

Table 61             Samsung Biologics: Major Service Offerings

Table 62             Meridian Life Science: Major Service Offerings

Table 63             Wacker Biotech B.V: Major Service Offerings

Table 64             Jubilant HollisterStier: Major Service Offerings

Table 65             AbbVie: Major Service Offerings

Table 66             Novasep: Major Service Offerings

Table 67             Kemwell Biopharma: Major Service Offerings

Table 68             Northway Biotech: Major Service Offerings

Table 69             Midas Pharma: Major Service Offerings

Table 70             Alcami: Major Service Offerings

Table 71             Cambrex: Major Service Offerings

Table 72             Asymchem: Major Service Offerings

Table 73             Pharmaceutics International: Major Service Offerings

Table 74             Sharp: Major Service Offerings

Table 75             Singota Solutions: Major Service Offerings

Table 76             Thermo Fisher Scientific: Major Service Offerings

Table 77             Kaneka Eurogentec: Major Service Offerings

Table 78             Richter-Helm BioLogics: Major Service Offerings

Table 79             Ology Bioservices: Major Service Offerings

Table 80             Corden Pharma: Major Service Offerings

Table 81             Cerbios Pharma: Major Service Offerings

Table 82             BSP Pharmaceuticals: Major Service Offerings

Table 83             JOINN Biologics: Major Service Offerings

Table 84             Eurofins Scientific: Major Service Offerings

Table 85             ProBioGen: Major Service Offerings

Table 86             Esco Aster: Major Service Offerings

Table 87             Genovior Biotech: Major Service Offerings

Table 88             AGC Biologics: Major Service Offerings

Table 89             EirGenix: Major Service Offerings

Table 90             Amaran Biotech: Major Service Offerings

Table 91             Eden Biologics: Major Service Offerings

Table 92             Abzena: Major Service Offerings

Table 93             Aldevron: Major Service Offerings

Table 94             Cell Culture Company: Major Service Offerings

Table 95             Taron Solutions: Major Service Offerings

Table 96             MabPlex: Major Service Offerings

Table 97             Axcellerate Pharma: Major Service Offerings

Table 98             WuXi Biologics: Major Service Offerings

Table 99             Therapure Biopharma: Major Service Offerings

Table 100           Global Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 ($ million)

Table 101           Global Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 (%)

Table 102           North America Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 ($ million)

Table 103           North America Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 (%)

Table 104           Europe Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 ($ million)

Table 105           Europe Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 (%)

Table 106           APAC Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 ($ million)

Table 107           APAC Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 (%)

Table 108           Latin America Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 ($ million)

Table 109           Latin America Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 (%)

Table 110           Middle East & Africa Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 ($ million)

Table 111           Middle East & Africa Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 (%)

Table 112           Global Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 ($ million)

Table 113           Global Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 (%)

Table 114           North America Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 ($ million)

Table 115           North America Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 (%)

Table 116           Europe Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 ($ million)

Table 117           Europe Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 (%)

Table 118           APAC Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 ($ million)

Table 119           APAC Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 (%)

Table 120           Latin America Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 ($ million)

Table 121           Latin America Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 (%)

Table 122           Middle East & Africa Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 ($ million)

Table 123           Middle East & Africa Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 (%)

Table 124           Global Vaccine Contract Manufacturing Market by Service 2020−2026 ($ million)

Table 125           Global Vaccine Contract Manufacturing Market by Service 2020−2026 (%)

Table 126           North America Vaccine Contract Manufacturing Market by Service 2020−2026 ($ million)

Table 127           North America Vaccine Contract Manufacturing Market by Service 2020−2026 (%)

Table 128           Europe Vaccine Contract Manufacturing Market by Service 2020−2026 ($ million)

Table 129           Europe Vaccine Contract Manufacturing Market by Service 2020−2026 (%)

Table 130           APAC Vaccine Contract Manufacturing Market by Service 2020−2026 ($ million)

Table 131           APAC Vaccine Contract Manufacturing Market by Service 2020−2026 (%)

Table 132           Latin America Vaccine Contract Manufacturing Market by Service 2020−2026 ($ million)

Table 133           Latin America Vaccine Contract Manufacturing Market by Service 2020−2026 (%)

Table 134           Middle East & Africa Vaccine Contract Manufacturing Market by Service 2020−2026 ($ million)

Table 135           Middle East & Africa Vaccine Contract Manufacturing Market by Service 2020−2026 (%)

Table 136           Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)

Table 137           Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)

Table 138           Commercial Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)

Table 139           Commercial Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)

Table 140           Clinical Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)

Table 141           Clinical Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)

Table 142           Preclinical Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)

Table 143           Preclinical Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)

Table 144           Sub-unit Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)

Table 145           Sub-unit Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)

Table 146           Live-attenuated Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)

Table 147           Live-attenuated Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)

Table 148           Inactivated Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)

Table 149           Inactivated Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)

Table 150           RNA Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)

Table 151           RNA Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)

Table 152           Others Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)

Table 153           Others Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)

Table 154           Fill/Finish Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)

Table 155           Fill/Finish Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)

Table 156           Analytical & QC Studies Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)

Table 157           Analytical & QC Studies Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)

Table 158           Cell/Virus banking Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)

Table 159           Cell/Virus banking Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)

Table 160           Others Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)

Table 161           Others Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)

Select a license type that suits your business needs

single-user Single User Licence
$3995.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4500.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5500.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date